A New Weapon in the War on Flu: Moderna's mRNA Vaccine Changes the Game
- Breakthrough Efficacy: Moderna's next-generation mRNA flu vaccine proved over 26% more effective than standard shots for adults 50+ in a massive global trial1, 2.
- Protecting the Vulnerable: The vaccine showed consistently strong results, offering even greater protection (27.4% rVE) for adults aged 65 and older1.
- A Glimpse of the Future: This technology promises more precise vaccines, rapid response to future pandemics, and the potential for a single COVID-flu combination shot1, 2, 5.
For years, the seasonal flu has been a relentless, unpredictable foe, particularly for older adults. The recent 2024-2025 season, with one of the highest hospitalization rates in 15 years, was a stark reminder of our vulnerability4. But now, the tide is turning.
Moderna has just unveiled a powerful new weapon in this fight: mRNA-1010. In a landmark Phase 3 study involving over 40,000 people across 11 countries, this revolutionary mRNA vaccine didn't just meet expectations—it shattered them1, 7. The results are staggering: mRNA-1010 demonstrated a 26.6% superior efficacy compared to a standard licensed flu shot in adults aged 50 and over, with even stronger protection against key strains like A/H1N11, 2, 3.
This isn't just an incremental improvement; it's a paradigm shift. As CEO Stéphane Bancel highlighted, mRNA technology allows for more precise matching against circulating strains and paves the way for rapid-response vaccines in a future pandemic1, 5. With a safety profile showing only mild and predictable reactions, mRNA-1010 is poised to become the new frontline defense, heralding a new era in the fight against influenza1, 6.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.